Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019
February 10, 2020 06:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial...
Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs
January 13, 2020 06:30 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis
December 19, 2019 17:40 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single...
Axovant Announces Amendment to Credit Facility with Hercules Capital
December 03, 2019 07:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only...
Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis
November 18, 2019 07:30 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the...
Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019
November 08, 2019 08:00 ET
|
Axovant Sciences Ltd.
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in AXO-AAV-GM1...
Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019
November 05, 2019 08:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that...
Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress
October 23, 2019 07:00 ET
|
Axovant Sciences Ltd.
Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRIAXO-AAV-GM2 generally safe and...
Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress
October 10, 2019 08:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...
Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa
September 25, 2019 16:05 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani,...